Last reviewed · How we verify
JMKX003002 will be administered orally
At a glance
| Generic name | JMKX003002 will be administered orally |
|---|---|
| Also known as | JMKX003002 |
| Sponsor | Jemincare |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia (PHASE2)
- Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMKX003002 will be administered orally CI brief — competitive landscape report
- JMKX003002 will be administered orally updates RSS · CI watch RSS
- Jemincare portfolio CI